The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASH 2018 | Pembrolizumab for R/R PMBCL patients: Results from the phase II Keynote-170 trial and updated data from the phase Ib Keynote-013

Jan 2, 2019

On Saturday 1 December 2018, Oral Session 626took place at the 60 thAmerican Society of Hematology (ASH) Annual Meeting, San Diego, CA. During that session, through Abstract #228the updated results of the Keynote-013 (KN013) phase Ib trial and the first analysis of its subsequent phase II trial Keynote-170 (KN170), were presented by Philippe Armandfrom the Dana-Farber Cancer Institute, Boston, MA, USA.

In the primary analysisof the phase Ib KN013 study ( NCT01953692), relapsed or refractory (R/R) patients with primary mediastinal large B-cell lymphoma (PMBCL), achieved frequent and durable responses with pembrolizumab. They achieved an objective response rate (ORR) of 41% and a complete response rate of 12%. Here the investigators presented the updated results from this phase Ib trial together with the primary phase II analysis ( NCT02576990) on the efficacy and safety of pembrolizumab in R/R PMBCL. Pembrolizumab is a humanized IgG4 anti-PD1 monoclonal antibody. The primary endpoint of KN170 was ORR by blinded independent central review (BICR). Secondary endpoints included, progression-free survival (PFS), overall survival (OS), and safety. Exploratory endpoints included response by Lugano 2014 criteria.

Study designs & baseline characteristics

  • KN013 (phase Ib):
    • Data cut-off: 4 April 2018
    • N = 21 (17 evaluable) R/R PMBCL patients, who had failed, were ineligible for, or refused autologous stem cell transplant (ASCT).
    • The initial 10 patients received pembrolizumab 10 mg/kg every two weeks [Q2W]; while the next 11 patients received pembrolizumab 200 mg every three weeks [Q3W] for up to 2 years or until unacceptable toxicity, disease progression or patient/physician withdrawal decision
    • Archival or fresh tumor tissue obtained before pembrolizumab initiation was used for correlative studies
    • Tumor response was assessed with positron emission tomography/computerized tomography (PET/CT) scans according to the International Working Group (IWG) 2007 criteria either:
      • At Week 12 and then every eight weeks for the 10 mg/kg cohort
      • At Week 6 and 12 and then every three weeks for the 200 mg cohort
    • Median patient age (range): 31 (22−62)
    • Median number of prior lines (range): 3 (2−9)
    • Prior radiation: 71% of patients
  • KN170 (phase II):
    • Data cut-off: 13 April 2018
    • N = 53 R/R PMBCL, who had relapsed after or were ineligible for ASCT with ≥ 2 lines of prior therapy
    • All patients received pembrolizumab 200 mg Q3W for up to 2 years or until unacceptable toxicity, disease progression or patient/physician withdrawal decision
    • Archival or fresh tumor tissue obtained before pembrolizumab initiation was used for correlative studies
    • Tumor response was assessed by PET/CT scans at Week 12 and then every twelve weeks according to the IWG 2007 criteria
    • Median patient age (range): 33 (20−61)
    • Median number of prior lines (range): 3 (2−8)
    • Prior radiation: 32% of patients

Results

KN170 (phase II) primary analysis:

  • Median follow-up (range): 12.5 (0.1−6) months
  • Median time to response: 2.8 months
  • Response rates by Lugano criteria:
    • Overall response: 43% (n = 23)
    • Complete response (CR): 21% (n = 11)
    • Partial response (PR): 22% (n = 12)
    • Stable disease (SD): 9% (n = 5)
    • Progressive disease (PD): 25% (n = 13)
    • Non-evaluable: 23% (n = 12)
  • Response rates by Cheson criteria:
    • Overall response: 45% (n = 24)
    • Complete response (CR): 13% (n = 7)
    • Partial response (PR): 32% (n = 17)
    • Stable disease (SD): 9% (n = 5)
    • Progressive disease (PD): 23% (n = 12)
    • Non-evaluable: 23% (n = 12)
  • No patient with CR had relapsed at data cut-off
  • 12-month PFS: 38%
  • Median PFS: 5.5 (95% CI, 2.8−1) months
  • 12-month OS: 58%
  • Median OS: not reached (95% CI, 7.3−not reached)

KN013 (phase Ib) updated results:

  • Median duration of follow-up (range): 29.1 (0.6−6) months
  • Median time to response: 2.7 months
  • Two patients in CR at two years, remained in CR after a further 12 and 18 months of follow-up therapy
  • 12-month PFS: 47%
  • Median PFS: 10.4 (95% CI, 3.4−not reached) months
  • 12-month OS: 65%
  • Median OS: 31.4 (95% CI, 4.9−not reached) months

Safety

KN170 (phase II) primary analysis:

  • Treatment-emergent adverse events (TEAEs) of all grades occurred in 57% of patients (n = 30)
  • Grade 3−4 TEAEs occurred in 23% of patients (n = 12)
  • Most common Grade 3−4 TEAEs were:
    • Neutropenia: 13%
    • Febrile neutropenia: 2%
    • Increased alanine aminotransferase (ALT): 2%
    • Increase aspartate aminotransferase (AST): 2%
    • Clostridium difficile infection: 2%
    • Pneumonia: 2%
    • Tumor flare: 2%
    • Venous thrombosis: 2%
  • Immune-mediated AEs of any grade occurred in 11% (n = 6) of patients
  • Grade 3−4 immune-mediated AEs occurred in one patient (pneumonitis)

KN013 (phase Ib) updated results:

  • Treatment-emergent adverse events (TEAEs) of all grades occurred in 71% of patients (n = 15)
  • Grade 3−4 TEAEs occurred in 24% of patients (n = 5)
  • Most common Grade 3−4 TEAEs were:
    • Neutropenia: 14%
    • Febrile neutropenia: 5%
    • Increased ALT: 5%
    • Fatigue: 5%
    • Hyponatremia: 5%
  • Immune-mediated AEs of any grade occurred in 19% (n = 4) of patients
  • Grade 3−4 immune-mediated AEs occurred in one patient (myositis)

  Conclusions

  • Pembrolizumab leads to frequent and durable response in heavily pre-treated R/R PMBCL patients
  • The median DoR was not reached with a median follow-up of 29.1 months in KN013 or with a median follow-up of 12.5 months in KN170
  • At least 50% of patients were alive at one year after treatment in both studies
  • Pembrolizumab has a manageable safety profile in R/R PMBCL patients
  • The presented data provided the basis for the accelerated approval of pembrolizumab for R/R PMBCL patients from the Food and Drug Administration (FDA), US on 13 June 2018
  1. Armand P. et al.Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. Oral Session 626, Abstract #228: ASH 60th Annual Meeting and Exposition , December 2018, San Diego, CA